Avinger (AVGR) Posts Q1 Loss of $5.37/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Avinger Announces First Quarter 2018 Financial Results
May 14, 2018 4:15 PM EDTREDWOOD CITY, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the first quarter ended March 31, 2018. Â
First Quarter and Recent Highlights
Revenue of $1.8 million for the first quarter of 2018Announced treatment of first patients globally with next generation Pantheris Lumivascular atherectomy system  Added the extended nosecone version of next generation Pantheris and announced successful first-in-patient procedures in EuropeNext generation Pantheris featured in live case transmissions at Leipzig Interventional Course... More